6.7.6. first-line treatment metastatic crpc. 6.7.6.1. abiraterone abiraterone evaluated 1,088 chemo-naive, asymptomatic mildly symptomatic mcrpc patients phase iii cou-aa-302 trial. patients randomised abiraterone acetate placebo, combined prednisone . patients visceral metastases excluded. main stratification factors ecog ps 0 1 asymptomatic mildly symptomatic disease. overall survival rpfs co-primary endpoints. median follow-up 22.2 months significant improvement rpfs (median 16.5 vs. 8.2 months, hr: 0.52, p < 0.001) trial unblinded. final analysis median follow-up 49.2 months, os endpoint significantly positive (34.7 vs. 30.3 months, hr: 0.81, 95% ci: 0.70–0.93, p = 0.0033) . adverse events related mineralocorticoid excess liver function abnormalities frequent abiraterone, mostly grade 1–2. subset analysis trial showed drug equally effective elderly population (> 75 years) . 6.7.6.2. enzalutamide randomised phase iii trial (prevail) included similar patient population compared enzalutamide placebo . men visceral metastases eligible numbers included small. corticosteroids allowed mandatory. prevail conducted chemo-naive mcrpc population 1,717 men showed significant improvement co-primary endpoints, rpfs (hr: 0.186, ci: 0.15–0.23, p < 0.0001), os (hr: 0.706, ci: 0.6–0.84, p < 0.001). ≥ 50% decrease psa seen 78% patients. common clinically relevant aes fatigue hypertension. enzalutamide equally effective well tolerated men > 75 years well without visceral metastases . however, men liver metastases, seemed discernible benefit . enzalutamide also compared bicalutamide 50 mg/day randomised double-blind phase ii study (terrain) showing significant improvement pfs (15.7 months vs. 5.8 months, hr: 0.44, p < 0.0001) favour enzalutamide . extended follow-up final analysis benefit os rpfs confirmed . 6.7.6.3. docetaxel statistically significant improvement median survival 2.0–2.9 months shown docetaxel based chemotherapy compared mitoxantrone plus prednisone . standard first-line chemotherapy docetaxel 75 mg/m2, three-weekly doses combined prednisone 5 mg twice day (bid), ten cycles. prednisone omitted contra-indications major symptoms. following independent prognostic factors: visceral metastases, pain, anaemia (hb < 13 g/dl), bone scan progression, prior estramustine may help stratify response docetaxel. patients categorised three risk groups: low risk (0 1 factor), intermediate (2 factors) high risk (3 4 factors), show three significantly different median os estimates 25.7, 18.7 12.8 months, respectively . age contra-indication docetaxel attention must paid careful monitoring comorbidities discussed section 5.4 - estimating life expectancy health status . men mcrpc thought unable tolerate standard dose schedule, docetaxel 50 mg/m2 every two weeks seems well tolerated less grade 3–4 aes prolonged time treatment failure . 6.7.6.4. sipuleucel-t 2010 phase iii trial sipuleucel-t showed survival benefit 512 asymptomatic minimally symptomatic mcrpc patients . median follow-up 34 months, median survival 25.8 months sipuleucel-t group compared 21.7 months placebo group, hr 0.78 (p = 0.03). psa decline observed pfs similar arms. overall tolerance good, cytokine-related aes grade 1–2 sipuleucel-t group, grade 3–4 aes arms. sipuleucel-t available europe. 6.7.6.5. ipatasertib akt inhibitor ipatasertib combination aap studied asymptomatic mildly symptomatic patients without pten loss ihc previously untreated mcrpc. randomised phase iii trial (ipatential) showed significant benefit first endpoint rpfs pten loss (ihc) 18.5 vs. 16.5 mo; p = 0.0335, hr: 0.77, 95% ci: 0.61–0,98) intention treat (itt) population. os results still pending. side effects akt inhibitor ipatasertib include rash diarrhoea . grade 3 higher aes occurred nearly double often combination group discontinuation rate due aes four times higher. combination still investigational . 6.7.6.6. combinations parp inhibitors based suggestion synergistic antitumour effect combining arpi parp inhibitor, several combination trials conducted first-line mcrpc patients different trial designs, different patient selection conflicting results. abiraterone/prednisone plus olaparib randomised double-blind, phase iii trial (propel) aap plus olaparib (300 mg twice daily) placebo patients mcrpc first-line setting conducted . patients (n=796) randomly assigned 1:1 study treatment regardless homologous recombination repair gene mutation (hrrm) status retrospectively evaluated determined tumour tissue circulating tumour dna tests. primary end point imaging-based pfs (ibpfs) investigator assessment. result significantly positive favour combination ibpfs 24.8 vs. 16.6 mo (hr 0.66; 95% ci: 0.54 0.81; p = 0.001). prespecified final analyses key secondary endpoint os 47.9% maturity meet prespecified 2-sided boundary significance (hr 0.95% ci: 0.81, 0.67-1.0, p= 0,054).the subgroup patients positive hrrm status showed rpfs hr 0.50 (ci: 0.34 0.73). brca mutated patients (11% itt population) even larger benefit rpfs (hr 0.24; 95% ci: 0.12, 0.45) os hr patients 0.30 (95% ci: 0.15, 0.59), suggesting improvement rpfs observed itt population primarily driven patients brca mutation . common aes patients receiving olaparib plus aap anaemia (48%; ≥g3 15%; least one blood transfusion 18%; multiple transfusions 12% . common adverse reactions olaparib plus abiraterone anaemia (48%), fatigue (38%), nausea (30%), diarrhoea (19%), decreased appetite (16%), lymphopenia (14%), dizziness (14%), abdominal pain (13%); 18% patients required least one blood transfusion 12% required multiple transfusions. combination olaparib plus aap approved ema treatment adult patients mcrpc chemotherapy clinically indicated . us, fda approved olaparib aap mcrpc patients deleterious suspected deleterious brca-mutations determined fda-approved companion diagnostic test . abiraterone/prednisone plus niraparib randomised, double-blind, phase iii trial (magnitude) aap plus niraparib 200 mg once/daily placebo, evaluated . study prospectively included 2 cohorts, hrr-negative hrr-positive cohort. hrr-negative cohort closed early futility enrolling 200 patients. overall hrr-positive cohort, addition niraparib aap resulted significant improvement first endpoint rpfs compared aap plus placebo (hr = 0.73; 95% ci 0.56-0.96; p = 0.0217) median rpfs 16.5 vs. 13.7 months favour combination. particular, 113 patients brca 1/ 2 mutations received aap plus niraparib derived major rpfs benefit (19.5 versus 10.9 months; hr = 0.55 [95% ci 0.39-0.78]; nominal p = 0.0007). os data still immature. common side effects niraparib plus aap itt population anemia (46.2%), fatigue (26.4%), hypertension (31.6%) constipation (30.7%). combination niraparib plus aap dual-action tablet approved ema fda patients mcrpc brca 1/2 mutations chemotherapy clinically indicated . enzalutamide plus talazoparib randomised double-blind, phase iii trial (talapro-2) parp inhibitor talazoparib (0.5mg daily) plus enzalutamide versus enzalutamide/placebo showed significantly better median rpfs (first endpoint) favour combintion regardless homologous recombination repair pathway status . median yet reached combination compared 21.9 mo control arm (95% ci 16.6-25.1). hr rpfs 0.63 (0.51-0.78) p<0.0001. subgroups patients hrr mutations benefit combination much pronounced. hrr gene-mutated population showed median rpfs 27.9 (16.6–not reached) talazoparib combination versus 16.4 (10.9–24.6) placebo group (0.46; 95% ci: 0.30–0.70; p=0.0003 ) 0.70 (0.54–0.89; p=0.0039) patients status non-deficient unknown. exploratory analysis, hr rpfs patients brca-mutated mcrpc 0.23 (0.10–0.53; p=0.0002) and, patients non-brcam hrr gene-mutated mcrpc, 0.66 (0.39–1.12; p=0.12) favour talazoparib combination. os data still immature. expected clinical benefit subgroups needs weighed potential burden side effects. common treatment-emergent adverse events addition talazoparib anaemia, neutropenia, fatigue; common grade 3–4 event anaemia (46%), improved dose reduction, however, 39% required blood transfusion, including 22% required multiple transfusions, 8% discontinued treatment due anemia 2 patients combination diagnosed myelodysplastic syndrome/acute myeloid leukemia . talapro-2 also hrr-deficient-only cohort (cohort 2; n = 230) recruited. primary analysis combined hrr-deficient population (n = 399) met rpfs endpoint hr 0.45 (95% ci, 0.33 0.61; p < 0.0001; median reached time analysis talazoparib group versus 13.8 months placebo group). also cohort data os immature favor talazoparib (hr 0.69; 95% confidence interval, 0.46 1.03; p = 0.07) . fda approved talazoparib enzalutamide hrr gene-mutated mcrpc . european commission approved talazoparib enzalutamide treatment patients mcrpc (with without gene mutations) chemotherapy clinically indicated. table 6.7.2: randomised phase iii controlled trials - first-line treatment mcrpc studyinterventioncomparisonselection criteriamain outcomesdocetaxelswog 99-162004 docetaxel/emp,every 3 weeks,60 mg/m2, emp3 x 280 mg/daymitoxantrone,every 3 weeks,12 mg/m2 prednisone 5 mg bidos: 17.52 vs. 15.6 mo. (p = 0.02, hr: 0.80; 95% ci: 0.67-0.97) pfs: 6.3 vs. 3.2 mo.(p < 0.001)tax 3272004, 2008docetaxel, every3 weeks, 75 mg/m2prednisone 5 mg bidordocetaxel, weekly, 30 mg/m2prednisone 5 mgbidmitoxantrone,every 3 weeks,12 mg/m2, prednisone 5 mg bidos: 19.2 3 weekly vs. 17.8 mo. 4-weekly 16.3 control group.(p = 0.004, hr: 0.79, 95% ci: 0.67-0.93)abirateronecou-aa-3022013, 2014, 2015 abiraterone +prednisoneplacebo + prednisone- previous docetaxel.- ecog 0-1.- psa radiographic progression.- mild symptoms.- visceral metastases.os: 34.7 vs. 30.3 mo. (hr: 0.81, p = 0.0033). fu: 49.2 mo. rpfs: 16.5 vs. 8.3 mo.(p < 0.0001)enzalutamideprevail2014 enzalutamideplacebo- previous docetaxel.- ecog 0-1.- psa radiographic progression.- mild symptoms.- 10% visceral mets.os: 32.4 vs. 30.2 mo. (p < 0.001). fu: 22 mo. (p < 0.001 hr: 0.71, 95% ci: 0.60-0.84) rpfs: 20.0 mo. vs.5.4 mo. hr: 0.186 (95% ci: 0.15-0.23)p < 0.0001)sipuleucel-timpact 2010 sipuleucel-tplacebo- previous docetaxel.- ecog 0-1.- asymptomatic minimally symptomatic.os: 25.8 vs. 21.7 mo. (p = 0.03 hr: 0.78, 95% ci: 0.61-0.98).fu: 34.1 mo. pfs: 3.7 vs. 3.6 mo. (no difference)2006 sipuleucel-tplacebo- ecog 0-1.- visceral met.- corticosteroids.os: 25.9 vs. 21.4 mo. (p = 0.1). fu: 36 mo. pfs: 11.7 vs. 10.0 wk.ipatasertibipatential1502021 ipatasertib (400 mg/d) + abiraterone (1000 mg/d) + prednisone(5 mg bid)abiraterone + prednisolone + placebopreviously untreated mcrpc, asymptomatic/mildly symptomatic, without pten loss ihcrpfs pten loss (ihc) population: 18.5 vs. 16.5 mo.(p = 0.0335, hr: 0.77 95% ci: 0.61-0.98)combinationspropel olaparib (300mg bid)+ abiraterone (1000 mg/d) + prednisone (5 mg bid)placebo + abiraterone + prednisone-ecog 0-1- regardless hrrm (retrospective testing)- prior taxane mhspc allowedibpfs itt population:24.8 vs. 16.6 mo; hr: 0.66; 95% ci: 0.54–0.81;(p = 0.001)ibpfs brca+:hr 0.24; 95% ci: 0.12- 0.45os itt population: 42.1 vs. 34.7 mo; hr 0.81; 95% ci:0.67-1.0;(p= 0.054)os brca+: hr 0.29; 95% ci: 0.15- 0.56magnitude niraparib 200 mg/d + abiraterone (1000 mg/d plus prednisone 5 mg bid)placebo + abiraterone (1,000 mg/d plus prednisone 5 mg bid)- ecog 0-1- aap ≤ 4mo allowed mcrpc;- hrr-biomarker positive cohort- prior docetaxel mhspc allowed- prior arpi mhspc allowed- prior arpi mcrpc allowedrpfs (central review) hrr+:16.5 vs. 13.7 mohr = 0.73; 95% ci: 0.56-0.96; (p = 0.022)rpfs (central review) brca 1/ 2+:16.5 vs. 13.7 morpfs 19.5 versus 10.9 months; hr= 0.55; 95% ci 0.39-0.78; (nominal p= 0.0007)talapro-2 talazoparib (0.5mg/d) + enzalutamide 160mg/denzalutamide + placebo- ecog 0-1- all-comers: hhr deficient hrr non-deficient unknown-prior aap docetaxel allowed mhspcrpfs itt: nr (27.5-nr) vs. 21.9 mo;hr 0.63; 95% ci: 0.51-0.78 (p<0.0001);rpfs brca+:hr 0·23; 95%ci: 0.10–0.53; p=0·0002 bid = twice day; ci = confidence interval; ecog = eastern cooperative oncology group; emp = estramustine; fu = follow-up; hr = hazard ratio; mets. = metastases; mo = month; ib (imaging based); (r)pfs = (radiographic) progression-free survival; os = overall survival; ihc = immunohistochemistry ; hrrm = homologour recombination repair genes mutation; brca+ = brca gene mutated; itt = intention treat; bicr = blinded independent central review.